BAVA:VIE
Bavarian Nordic A/S
31,66 €
arrow_downward
-0,81%(-0,26) 1D
16 հոկ, 17:36:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
31,94 €
High
32,24 €
Low
31,66 €
Mkt. cap
2,80 մլրդ
Avg. vol.
17,00
Volume
0,00
52-wk high
32,47 €
52-wk low
22,96 €
No. of employees
2 հզր
Open
31,94 €
High
32,24 €
Low
31,66 €
Mkt. cap
2,80 մլրդ
Avg. vol.
17,00
Volume
0,00
52-wk high
32,47 €
52-wk low
22,96 €
No. of employees
2 հզր
News stories
From web sources and news partners
Simply Wall Street
·
42 րոպե առաջ
Phase 3 Lung Trials Could Be A Big Test For Insmed (INSM)
Kalkine Media
·
52 րոպե առաջ
Royal Bank of Canada Launches Bearish PLUS Securities on S&P 500 with Maturity in November 2027
TradingView
·
39 րոպե առաջ
News by CNBC TV18 on TradingView, 2026-10-17 — cnbctv:73cfdfea6094b:0
Yahoo Finance
·
1 ժամ առաջ
Dow (DOW) Stock Could Look Reasonable After a 43% Gain
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1,91 հզր
Founded01 հլս, 1992 թ.
Headquarters-
Sector-
Websitebavarian-nordic.com